Corcept Therapeutics (NASDAQ:CORT) & PainReform (NASDAQ:PRFX) Head-To-Head Survey

PainReform (NASDAQ:PRFX) and Corcept Therapeutics (NASDAQ:CORT) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, profitability, risk, earnings and dividends.

Volatility & Risk

PainReform has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500.

Insider & Institutional Ownership

37.3% of PainReform shares are held by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are held by institutional investors. 34.4% of PainReform shares are held by company insiders. Comparatively, 20.7% of Corcept Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares PainReform and Corcept Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PainReform	$20,000.00	33.63	-$5.02 million	($736.66)	-0.00
Corcept Therapeutics	$761.41 million	10.72	$99.65 million	$1.27	58.72

Corcept Therapeutics has higher revenue and earnings than PainReform. PainReform is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares PainReform and Corcept Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PainReform	N/A	N/A	N/A
Corcept Therapeutics	16.53%	22.56%	17.83%

Analyst Ratings

This is a summary of current ratings and price targets for PainReform and Corcept Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PainReform	1	0	0	0	1.00
Corcept Therapeutics	1	2	5	0	2.50

Corcept Therapeutics has a consensus target price of $139.50, suggesting a potential upside of 87.05%. Given Corcept Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Corcept Therapeutics is more favorable than PainReform.

Summary

Corcept Therapeutics beats PainReform on 11 of the 14 factors compared between the two stocks.

About PainReform

PainReform Ltd. (NASDAQ: PRFX) is a clinical-stage specialty pharmaceutical company focused on developing treatments for acute post-operative pain. The company’s work is aimed at addressing pain experienced after surgical procedures and reducing reliance on conventional short-acting analgesics. PainReform’s lead product candidate, PRF-110, is an extended-release formulation of ropivacaine, a local anesthetic. Designed for administration at the surgical site, PRF-110 is intended to provide prolonged pain relief during the days following surgery.

About Corcept Therapeutics

Corcept Therapeutics is a biopharmaceutical company focused on developing medicines that modulate the effects of cortisol, a hormone involved in the body’s response to stress and in several disease processes. Founded in 1998, the company conducts research and develops treatments for conditions in which cortisol may play a role. Its marketed product, Korlym (mifepristone), is approved in the United States to control high blood sugar in adults with endogenous Cushing’s syndrome who have type 2 diabetes or glucose intolerance and are not candidates for surgery or have not benefited from it.